GlycoFlux™ Human SIGLEC2 Overexpression A549 Cell Line (CAT#: GLJF-0925-JF880)

Description	GlycoFlux™ human SIGLEC2 overexpression A549 cell line is a stable glycoengineered model engineered to express SIGLEC2, a receptor with predicted CD4 receptor binding, protein phosphatase interaction, and sialic acid recognition activity. Localized to early and recycling endosomes, SIGLEC2 regulates B-cell activation, negatively modulates B-cell receptor signaling, and contributes to endocytic trafficking. Dysregulation has been implicated in diffuse large B-cell lymphoma. This epithelial model provides a platform to study immune lectin regulation, endosomal trafficking, and cancer-associated glycosylation changes.
Product Type	Overexpression Cell Lines
Species	Human
Cell Morphology	Epithelial-like, adherent
Passage Ratio	1:3~1:6
Cell Line	A549
Primary Disease	Non-small cell lung cancer
Lineage	Lung
Lineage Subtype	Non-small cell lung cancer

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	qPCR, Sanger Sequencing
Culture Medium	F-12K & FBS & Penicillin/Streptomycin
Application	Mechanistic studies; Exploration of glycosylation and signaling pathways in cancer, metabolic, and immune-related diseases; Drug target validation and other functional assays.
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	SIGLEC2
Full Name	Sialic Acid Binding Ig Like Lectin 2
Alternative Name	SIGLEC-2, CD22, Sialic Acid Binding Ig Like Lectin
Location	19q13.12
Gene ID	8778
Summary	Predicted to enable CD4 receptor binding activity; protein phosphatase binding activity; and sialic acid binding activity. Involved in B cell activation; negative regulation of B cell receptor signaling pathway; and regulation of endocytosis. Located in early endosome and recycling endosome. Implicated in diffuse large B-cell lymphoma.